Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity

Gut Microbes. 2020 Nov 9;12(1):1-18. doi: 10.1080/19490976.2020.1842990.

Abstract

Phlorizin (PHZ) is one of phytonutrients in apples that contributes to the health-promoting effect implicated by the saying, 'an apple a day keeps the doctor away'. PHZ was firstly identified as a competitive inhibitor of sodium-glucose co-transporters-2 (SGLT2); however, its low bioavailability makes it hard to fully explain its pharmacological mechanisms. This study aimed to investigate the ameliorating effect of PHZ on high-fat diet (HFD)-induced obesity via modulating the "gut microbiota-barrier axis". Firstly, C57BL/6 J mice were fed a normal chow diet (NCD) or HFD coadministered with or without PHZ for 12 weeks. Our results showed that PHZ supplementation significantly reduced HFD-induced body weight gain (P < .001), alleviated metabolic disorders (MDs) like insulin resistance (P < .001) and elevation of serum lipopolysaccharides (LPS) (P < .001), attenuated HFD-induced gut microbiota alterations, enhanced short-chain fatty acids (SCFAs) production (P < .001), and inhibited fecal LPS production (P < .001). To investigate the role of the fecal microbiota in the observed beneficial effects, a fecal microbiota transplantation (FMT) experiment was performed by transplanting the feces of the four groups of mice (as donor mice) daily collected from the fourth week to a new batch of acclimatized HFD-fed mice. Our results confirmed that feeding the gut contents of the PHZ-modulated mice could attenuate HFD-induced MDs, accompanied by enhanced glucagon-like peptide 2 (GLP-2) secretion (P < .001) and restoration of HFD-induced damage in the gut epithelial barrier. This study has provided evidence that the "gut microbiota-barrier axis" was an alternative target for the anti-obesity effect of PHZ. This work has also provided an explanation for the high efficacy of PHZ despite the low bioavailability, and PHZ holds great potential to be developed as a functional food ingredient.

Keywords: Phlorizin (PHZ); barrier integrity; glucagon-like peptide 2 (GLP-2); gut microbiota; obesity; short-chain fatty acids (SCFAs).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Obesity Agents / pharmacology*
  • Bacteria / classification
  • Bacteria / isolation & purification
  • Diet, High-Fat
  • Dietary Supplements
  • Endotoxemia / drug therapy*
  • Fatty Acids, Volatile / biosynthesis
  • Fecal Microbiota Transplantation
  • Gastrointestinal Microbiome / drug effects*
  • Insulin Resistance / physiology*
  • Lipopolysaccharides / blood
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Obesity / pathology
  • Phlorhizin / pharmacology*
  • Phytochemicals / pharmacology
  • Tight Junctions / drug effects*
  • Weight Gain / drug effects

Substances

  • Anti-Obesity Agents
  • Fatty Acids, Volatile
  • Lipopolysaccharides
  • Phytochemicals
  • Phlorhizin

Grants and funding

This work was supported by the Project of Science and Technology Ministry of Sichuan Province (Grant No. 2019YFS0107), the Key Cultivation Project of Sichuan Education Department (Grant No. 18CZ0005), and the Project of Science and Technology Department of Panzhihua city Sichuan University-Panzhihua City Science and Technology Cooperation Special Fund, (Grant No. 2019CDPZH-14)).